PetMed Express, Inc. (NASDAQ:PETS - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $4.33 and traded as high as $4.50. PetMed Express shares last traded at $4.48, with a volume of 327,233 shares traded.
Analysts Set New Price Targets
Separately, StockNews.com downgraded PetMed Express from a "buy" rating to a "hold" rating in a report on Tuesday, February 11th.
Get Our Latest Stock Analysis on PETS
PetMed Express Stock Down 2.2 %
The stock has a fifty day moving average of $4.92 and a 200-day moving average of $4.34. The firm has a market capitalization of $91.11 million, a P/E ratio of 441.44 and a beta of 0.70.
PetMed Express (NASDAQ:PETS - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.02). PetMed Express had a net margin of 0.14% and a return on equity of 0.37%. Sell-side analysts predict that PetMed Express, Inc. will post 0.19 EPS for the current fiscal year.
Insider Buying and Selling at PetMed Express
In other PetMed Express news, Director Leslie C.G. Campbell bought 15,000 shares of PetMed Express stock in a transaction dated Wednesday, December 4th. The stock was bought at an average cost of $5.38 per share, for a total transaction of $80,700.00. Following the purchase, the director now owns 70,000 shares of the company's stock, valued at $376,600. The trade was a 27.27 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.10% of the company's stock.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership boosted its stake in shares of PetMed Express by 26.5% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 513,381 shares of the company's stock worth $2,474,000 after acquiring an additional 107,614 shares during the period. Metavasi Capital LP boosted its stake in shares of PetMed Express by 48.5% during the 4th quarter. Metavasi Capital LP now owns 340,302 shares of the company's stock worth $1,640,000 after acquiring an additional 111,194 shares during the period. Geode Capital Management LLC boosted its stake in shares of PetMed Express by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 224,788 shares of the company's stock worth $1,084,000 after acquiring an additional 3,558 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of PetMed Express by 2.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 216,812 shares of the company's stock worth $1,045,000 after acquiring an additional 4,410 shares during the period. Finally, Man Group plc boosted its stake in shares of PetMed Express by 5.5% during the 4th quarter. Man Group plc now owns 145,796 shares of the company's stock worth $703,000 after acquiring an additional 7,646 shares during the period. 73.33% of the stock is currently owned by institutional investors.
PetMed Express Company Profile
(
Get Free Report)
PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.
Further Reading
Before you consider PetMed Express, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PetMed Express wasn't on the list.
While PetMed Express currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.